A pivotal trial of PLX-R18 in acute radiation syndrome (ARS)
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Avoplacel (Primary)
- Indications Acute radiation syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Pluri
- 28 Feb 2024 According to a Pluristem Therapeutics media release, In July 2023, company signed a 3-year, $4.2 million contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of our PLX-R18 cell therapy as a potential novel treatment for Hematopoietic Acute Radiation Syndrome (H-ARS).
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 10 May 2018 According to Pluristem Therapeutics media release, the company anticipates FDA clearance for this trial by the end of 2018.